Palatin Technologies (PTN) Corporate presentation summary

Company overview and leadership

• Focuses on melanocortin system therapeutics for obesity, rare MC4R diseases, and autoimmune conditions.

• Demonstrated expertise from discovery to FDA approval, including VyleesiⓇ for female sexual dysfunction.

• Leadership team has extensive experience in drug development, finance, operations, and business development.

Obesity and rare MC4R pathway disease programs

• Developing next-generation MC4R agonists: oral small molecule (PL7737) and once-weekly peptide for rare obesity indications (HO, PWS).

• PL7737 granted FDA orphan drug designation for obesity due to leptin receptor deficiency.

• Preclinical and animal studies show significant, dose-dependent weight loss with PL7737 and peptide agonists.

• IND filing for PL7737 planned 1H 2026; Phase 1 and 2/3 studies in HO & PWS patients targeted for late 2026.

• Peptide agonist IND and clinical studies planned for 2H 2026 and 2027, with focus on minimizing side effects.

Generalized obesity management and combination therapy

• Bremelanotide (MC4R agonist) shows significant weight loss and reduced caloric intake in obese subjects.

• Phase 2 BMT-801 study: co-administration of MC4R agonist and tirzepatide yields additive weight loss without increased safety issues.

• Data support MC4R agonists for weight loss maintenance and as adjuncts to incretin-based therapies.